


CAMSON BIO TECHNOLOGIES LIMITED

AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2017

Sl. No.	Particulars	STANDALONE				CONSOLIDATED	
		Quarter Ended		Twelve Months Ended		Twelve Months Ended	
		31st March 2017	31st December 2016	31st March 2016	31st March 2017	31st March 2016	31st March 2017
		Refer Note 2	(Unaudited)	Refer Note 2	(Audited)	(Audited)	(Audited)
1	(a) Revenue from operations (gross)	72.35	588.55	(589.45)	1,035.02	2,540.33	1,539.23
	(b) Less: Excise duty						
	(c) Revenue from operations (net) (a-b)	72.35	588.55	(589.45)	1,035.02	2,540.33	1,539.23
	(d) Other income	224.17	57.80	31.50	393.60	115.75	394.14
	Total revenue (c+d)	296.52	646.35	(557.95)	1,428.62	2,656.08	1,933.37
2	(a) Expenses	(29.30)	60.92	32.50	93.63	574.81	145.11
	(b) Cost of Materials consumed						
	(b) Purchase of stock-in-trade						
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(37.95)	80.20	121.27	153.88	(91.23)	264.68
	(d) Other Operating expenses	135.84	139.86	170.60	582.83	992.40	645.04
	(e) Employee benefits expenses	192.09	245.55	206.34	650.74	498.90	678.35
	(f) Finance costs	179.99	187.93	1,385.93	744.09	2,171.77	759.01
	(g) Depreciation and amortisation expenses	997.73	272.35	530.52	1,940.86	2,502.21	1,985.88
	(h) Other expenses	1,438.40	986.81	2,447.16	4,166.03	6,648.86	4,857.32
	Total Expenses	(1,141.88)	(390.46)	(2,979.11)	(2,737.41)	(3,992.78)	(2,923.95)
3	Profit before tax and exception item (1-2)						
4	Loss on dilution of interest in subsidiary (Refer Note 5)						(291.88)
5	Exceptional items						
6	Profit before tax (3+(4+5))	(1,141.88)	(390.46)	(2,979.11)	(2,737.41)	(3,992.78)	(3,215.93)
7	Tax Expenses	(11.42)	(39.13)	(277.60)	(17.05)	(209.30)	(208.78)
8	Profit for the year (6-7)	(1,130.46)	(351.93)	(2,701.51)	(2,720.36)	(3,783.48)	(3,195.88)
9	Share of profit from Associated Company						(193.35)
10	Minority Interest						(198.37)
11	Profit after share of Profit (8-(9+10))	(1,130.46)	(351.93)	(2,701.51)	(2,720.36)	(3,783.48)	(3,394.27)
12	Earnings per equity share (face value of Rs10/- each)	(3.77)	(1.17)	(9.01)	(9.07)	(12.61)	(11.31)
(a)	Basic	(3.77)	(1.17)	(9.01)	(9.07)	(12.61)	(11.31)
(b)	Diluted						



(14)

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2017


Sl. No	PARTICULARS	STANDALONE			CONSOLIDATED	
		31st March 2017 Refer Note 4	31st March 2016 Refer Note 4	31st March 2017 Refer Note 4	31st March 2016 Refer Note 4	
A	EQUITY AND LIABILITIES					
1	Shareholders' funds					
	(a) Share capital	2,999.98	2,999.98	2,999.98	2,999.98	
	(b) Reserves and surplus	4,703.29	7,423.65	4,703.29	7,162.92	
	Sub Total - Shareholders funds	7,703.27	10,423.63	7,703.27	10,162.90	
2	Minority Interest	-	-	-	225.80	
2	Non-current liabilities					
	(a) Long term borrowings	842.04	948.55	842.04	1,088.26	
	(b) Other long term liabilities	174.65	223.85	174.65	223.85	
	(c) Deferred tax liabilities (net)	-	-	-	-	
	(d) Long term provisions	54.58	55.39	54.58	66.27	
	Sub Total - Non current liabilities	1,071.27	1,227.79	1,071.27	1,378.38	
3	Current liabilities					
	(a) Short term borrowings	3,744.78	3,720.05	3,744.78	4,891.98	
	(b) Trade payables	750.77	696.93	750.73	1,507.72	
	(c) Other current liabilities	1,041.67	844.35	1,041.67	1,052.70	
	(d) Short term provisions	398.50	294.78	398.50	295.73	
	Sub Total - Current liabilities	5,935.72	5,545.51	5,935.68	7,758.13	
	TOTAL	14,710.26	17,196.93	14,710.22	19,525.21	
B	ASSETS					
1	Non-current assets					
	(a) Property, plant and equipment	8,576.37	9,395.46	8,576.37	10,619.92	
	(b) Intangible assets	931.48	1,166.45	931.48	1,301.45	
	(c) Intangible asset under development	-	-	-	1.36	
	(d) Goodwill on consolidation	-	-	-	0.25	
	(e) Non-current investments	340.00	597.91	340.00	-	
	(f) Deferred tax assets (net)	118.14	118.14	118.14	118.15	
	(g) Long term loans & advances	3,037.05	3,236.71	3,037.05	3,256.71	
	(h) Other non-current assets	2.68	2.50	2.68	8.24	
	Sub Total - Non-current assets	13,005.72	14,537.17	13,005.72	15,306.08	
2	Current Assets					
	(a) Inventories	1,191.65	923.94	1,191.65	1,088.85	
	(b) Trade receivables	371.57	1,659.71	371.53	2,862.25	
	(c) Cash & cash equivalents	20.77	30.21	20.77	59.25	
	(d) Short term loans & advances	65.63	45.90	65.63	208.77	
	(e) Other current assets	54.92	-	54.92	-	
	Sub Total - Current assets	1,704.54	2,659.76	1,704.50	4,219.13	
	TOTAL	14,710.26	17,196.93	14,710.22	19,525.21	



Notes :

1. The above audited consolidated results for the quarter and year ended March 31, 2017 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 29, 2017.
2. The figures for the quarter ended March 31, 2017 and March 31, 2016 are balancing figures between audited figures of the full financial year and the published year to date figures up to the third quarter for the respective financial year.
3. The Company received communication from shareholders alleging certain issues relating to financial matters of the Company with a request to conduct a forensic audit, which was also reported in the financial statements of the company for the financial year ended March 31, 2016. The Company requested the said shareholder to provide specific facts and scope/areas for the forensic audit. In the absence of specific details requested above, the Company's Board of Directors propose to carry out a forensic audit by appointing an independent committee/legal counsel to decide the scope and areas of forensic audit.
However, during the year the Company has not conducted the forensic audit. The Company is of the view that material adjustments or disclosures, if any, arising out of the forensic audit would be considered after conclusion of the forensic audit and the Management has not estimated the impact of any adjustment that may arise to the amounts and disclosures in the financial statements.
4. The auditors have expressed a disclaimer of opinion on financial statement for the year ended March 31, 2017 and March 31, 2016 and which is explained by management in the above mentioned note no 3.
5. The Company's operation comprise only of one segment viz., Agri Biotech Products.
6. During the year the company has not participated in the issuance of shares of Camson Agri Ventures Private Limited resulting in dilution of interest from Subsidiary to Associate.
7. Previous periods figures have been regrouped/ rearranged wherever necessary.

Place: Bengaluru
Date : May 29, 2017

For and on Behalf of Board of Directors

Veerendra Kumar Singh
Managing Director
